IBD patients are often told that our understanding of the GI tract and how to improve patient care improves every day, but the real challenge is ensuring that this knowledge reaches the people who need it most; the doctors and specialists working day-in and day-out to bolster the field through their research and hard work.
This year at the Advances in Inflammatory Bowel Diseases (AIBD) Conference in Orlando, over 2,500 medical professionals, biotechnologists, and researchers gathered to hear about the CurQD® Protocol, Evinature’s flagship nutraceutical. CurQD® took the spotlight not once, not twice, but three separate times, with global experts highlighting CurQD® in their keynote presentations. This recognition solidifies CurQD®’s position as a revolutionary new treatment for improving IBD.
CurQD®: The Highlight of AIBD 2024
The AIBD Conference brings together leading experts in gastroenterology from around the world to explore advancements in IBD treatment. Thousands of attendees, ranging from biotech start-ups to renowned researchers, spent three days presenting and debating their latest findings.
Amid this competitive landscape, CurQD® emerged as a major talking point, with multiple speakers emphasizing its efficacy and clinical significance. “Throughout the conference,” noted IBD patient advocates Tina Aswani-Omprakash and Natalie Hayden in their key takeaways from AIBD 2024, “CurQD received many notable mentions.”
The recognition extended beyond the conference itself. The journal Gastroenterology & Hepatology featured CurQD® as a highlight from AIBD, citing studies that demonstrated its “greater efficacy than placebo for inducing response and remission… [and] to reduce bowel urgency in patients.”
Recognized by Leading Experts
Dr. Maia Kayal
Dr. Maia Kayal, Assistant Professor of Gastroenterology at the Icahn School of Medicine at Mount Sinai, presented groundbreaking research published in the Journal of Crohn’s and Colitis. “Dr. Kayal shared this placebo-controlled trial,” wrote Aswani-Omprakash and Hayden, “that found CurQD was effective for inducing response and remission in active UC patients and has the ability to significantly decrease urgency.”
The study focused on one of the most debilitating symptoms of IBD—bowel urgency—and found that 70% of participants experienced significant improvements, highlighting CurQD® as a natural, clinically proven solution to enhance patients’ quality of life.
Dr. Bruce Sands
An internationally recognized expert and Chief of the Dr. Henry D. Janowitz Division of Gastroenterology at Mount Sinai, Dr. Sands showcased our multicenter, randomized, double-blind, placebo-controlled study on CurQD®. The research demonstrated CurQD®’s clear advantage in combination therapy for active ulcerative colitis. The findings emphasized CurQD®’s potential to complement existing treatments, making it a pivotal tool in enhancing IBD care and management.
Dr. Dawn B. Beaulieu
Founder of the first Functional Medicine IBD Clinic in the U.S. and an Associate Professor at Vanderbilt University, Dr. Beaulieu highlighted the recently published benefits of CurQD® in pediatric ulcerative colitis treatment. Her presentation emphasized the protocol’s role in reducing gut inflammation, improving restoration, and transforming the quality of life for young patients.
Dr. David T. Rubin
Dr. David T. Rubin, Chief of Gastroenterology at the University of Chicago Medicine, “touted CurQD as an adjunctive IBD therapy option, rather than a singular therapy,” recalled Aswani-Omprakash and Hayden. Dr. Rubin is a world-renowned expert in inflammatory bowel diseases (IBD), leading groundbreaking research, clinical advancements, and guideline development while holding key roles in major gastroenterological organizations.
A Testament to Innovation
Evinature’s mission is to revolutionize IBD patient care through cutting-edge, plant-based nutraceuticals backed by robust clinical research. The spotlight on CurQD® at AIBD reflects the culmination of years of dedicated research and collaboration. Dr. Shomron Ben-Horin, Evinature’s Chief Medical Officer and co-founder, encapsulated this achievement, saying, “It has been a long journey of CurQD® research. Evinature has matured to bring a novel plant-based agent to help IBD patients all over the globe!”
Looking Ahead
Through increasing awareness and continued research, Evinature aims to expand access to CurQD® and its benefits for more IBD patients worldwide. Backed by high-quality studies and endorsed by leading experts, CurQD® stands at the forefront of innovative IBD treatments. As demonstrated at AIBD, the future of IBD patient care is here, and Evinature is honored to be able to change the lives of thousands worldwide.
Summer Pitocchelli-Schwartzman
